AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04339270
Drug: Azithromycin according to rheology or symptoms
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Treatment according to standard COPD management, except for the prescription of azithromycin, which will be prescribed in function of mucus rheology or as a function of sputum complaints (here defined by a CASA-Q sputum symptoms score \<70).~The rheology of mucus will be quantified every 3 months.~* If the patient has spontaneous or induced sputum, and this sputum has a critical constraint (tau-C) \> 39, a prescription for 3 months of azithromycin treatment will be initiated. This prescription may be renewed every 3 months during the 12 months of follow-up planned in this study.~* If the patient has a sputum symptoms score \<70, a prescription for 3 months of azithromycin treatment will be initiated. This prescription can be renewed every 3 months during the 12 months of follow-up planned in this study, if the patient continues to obtain a sputum symptoms score \<70.~* If the patient has a sputum symptoms score\> 70, management is not changed.
Trial: NCT06275204
Drug: Standard triple therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants who are positive for H. pylori will receive a standard triple therapy:~Antibiotic 1 - Amoxicillin 2 x 1000 mg, Antibiotic 2 - Clarithromycin 2 x 500 mg, Proton pump inhibitor - Esomeprazole 2 x 40 mg.
Trial: NCT04969731
Drug: Immuncell-LC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV
Trial: NCT00261560
Drug: acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06726369
Drug: MK-6204 (SKB535) for Injection
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-6204 (SKB535) for injection is administered every 3 weeks (q3w) until radiographic disease progression (PD), intolerable toxicity, death, or discontinuation of treatment, whichever occurs first.
Trial: NCT06726850
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the placebo arm, participants will consume a placebo matching GenSci1-144 for 12 consecutive weeks.
Trial: NCT06726850
Drug: GS1-144
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the GS1-144 arm, participants will receive multiple doses of GS1-144 tablets for 12 consecutive weeks
Trial: NCT06427447
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (gemcitabine plus capecitabine)
Trial: NCT06439563
Drug: JP-1366 10 mg
RxNorm normalized name: ALCOHOL 70 mL in 100 mL TOPICAL GEL [JP P Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JP-1366 10 mg, tablet, orally once a day for up to 24 weeks
Trial: NCT06439563
Drug: Lanston Capsule 15 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lanston Capsule 15 mg orally once a day for up to 24 weeks
Trial: NCT06439563
Drug: JP-1366 10 mg placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JP-1366 10 mg placebo, tablet, orally once a day for up to 24 weeks
Trial: NCT06439563
Drug: Lanston Capsule 15 mg placebo
RxNorm normalized name: PLACEBO CAP/TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lanston Capsule 15 mg placebo, orally once a day for up to 24 weeks
Trial: NCT06729021
Drug: LMWH
RxNorm normalized name: Low-molecular-weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular-weight heparin may be used after procedure by the decision of the doctor
Trial: NCT06716203
Drug: Drug: 5 mg BGM0504 Administered SC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: BGM0504 Administered SC
Trial: NCT06716203
Drug: Drug: : 10 mg BGM0504 Administered SC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: BGM0504 Administered SC
Trial: NCT06716203
Drug: Drug: Placebo Administered SC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: Placebo Administered SC
Trial: NCT06721494
Drug: Sterile Saline
RxNorm normalized name: Aqua Care Sterile Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile Saline for intravenous administration
Trial: NCT06721494
Drug: CS-1103
RxNorm normalized name: MyoGesic-CS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CS-1103 for intravenous administration
Trial: NCT06727864
Drug: 4-month regimen (2HERZ/2HRE)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-month (2HERZ/2HRE)
Trial: NCT06727604
Drug: IMVT-1402
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg SC QW for 52 weeks
Trial: NCT06727604
Drug: IMVT-1402
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg SC QW for 26 weeks followed by Placebo SC QW for 26 weeks
Trial: NCT06727604
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SC QW for 52 weeks
Trial: NCT06727734
Drug: Piroxicam
RxNorm normalized name: Piroxicam
DrugBank: Piroxicam (DB00554)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Piroxicam 40 mg
Trial: NCT06727734
Drug: Placebo - LNG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo of levonorgestrel
Trial: NCT06727734
Drug: Placebo - Piroxicam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo of piroxicam
Trial: NCT06727734
Drug: Placebo - UPA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo of ulipristal acetate
Trial: NCT05355441
Drug: Ibuprofen 600 mg
RxNorm normalized name: ibuprofen 600 MG
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Routine clinical practice treatments recommended by the medical team involved
Trial: NCT06722586
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo two pills per day
Trial: NCT06731192
Drug: Placebo control drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This group of patients received a total of 2 intravenous infusions of normal saline (the same volume, specifications and batches used in the experimental group) as a placebo control during the treatment period on the basis of conventional symptomatic and supportive treatment. The interval between the two infusions was 14 days.~Conventional clinical treatment refers to symptomatic treatment with ACEI and ARB drugs.
Trial: NCT06731868
Drug: LPM3770164 sustained release tablet 5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LPM3770164 sustained release tablet once daily oral dosage at 5 mg for 6 weeks
Trial: NCT06731868
Drug: LPM3770164 sustained release tablet 10 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LPM3770164 sustained release tablet once daily oral dosage at 10 mg for 6 weeks.
Trial: NCT06731868
Drug: LPM3770164 sustained release tablet 20 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LPM3770164 sustained release tablet once daily oral dosage at 20 mg for 6 weeks.
Trial: NCT06731868
Drug: LPM3770164 sustained release tablet simulant
RxNorm normalized name: STAPHYLOCOCCUS SIMULANS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LPM3770164 sustained release tablet simulant once daily oral for 6 weeks.
Trial: NCT06730542
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive Methotrexate as per standard of care (SOC).
Trial: NCT06730542
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive Cyclophosphamide as per standard of care (SOC), as part of combination standard of care Pola-R-CHP therapy.
Trial: NCT06730542
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive Doxorubicin as per standard of care (SOC), as part of combination standard of care Pola-R-CHP therapy.
Trial: NCT06592261
Drug: Insulin regular, 2.0-3.2 mU/m2/min (euinsulinemia)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin infusion to recapitulate euinsulinemia (normal basal insulin)
Trial: NCT06735079
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo serves as a control to evaluate the effectiveness and safety of REL-1017. It is an inactive substance that matches the active drug in appearance but contains no active ingredients. The placebo group allows researchers to compare outcomes, such as changes in depressive symptoms, with the active drug group.~The double-blind design ensures neither participants nor researchers know who is receiving the active treatment or placebo, eliminating bias. The placebo also helps assess whether observed side effects are due to the drug or unrelated factors.~Participants are randomly assigned to receive either REL-1017 or the placebo, both administered once daily for 28 days. This helps establish REL-1017's clinical effectiveness and safety in treating Major Depressive Disorder (MDD).
Trial: NCT06735235
Drug: 250 ppm F as MFP
RxNorm normalized name: F
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each subject will be randomly assigned to this treatment during one of the four periods for this crossover study.
Trial: NCT06735235
Drug: 1100 ppm as MFP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each subject will be randomly assigned to this treatment during one of the four periods for this crossover study.
Trial: NCT06735235
Drug: 2800 ppm F as MFP
RxNorm normalized name: F
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each subject will be randomly assigned to this treatment during one of the four periods for this crossover study.
Trial: NCT06732388
Drug: Placebo Administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT06733298
Drug: [ 14C]-labeled RO7269162
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive one oral dose of \[14C\]-labeled RO7269162.
Trial: NCT06737549
Drug: Placebo injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive 2ml volume of physiological saline (PS) injected intramuscularly into the gluteal muscle, three times a week for 6 weeks.
Trial: NCT05281523
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered as normal saline using a pre-filled syringe.
Trial: NCT04629547
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be taken nightly for 24 months.
Trial: NCT04944524
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1. Methotrexate (15 mg/week initially and progressively increased every week by 2.5 mg, to a maximum and optimal dose of 20 mg/week)~2. Basic treatment with prednisone. (1) the initial dose of prednisone (or equivalent): 0.8mg/kg/day. (2) Glucocorticoids tapering: after two weeks' usage of initial glucocorticoids dose, glucocorticoids can be tapered if there's no disease activity (BVAS/WG=0) or at least 50% reduction of BVAS/WG and no new manifestations. Prednisone (or equivalent) was reduced to 10mg/d at the time of randomization.
Trial: NCT05047952
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A placebo pill will be taken once daily.
Trial: NCT05903859
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants in this group will receive a placebo pill by mouth twice a day for a total of 90 days.
Trial: NCT06736327
Drug: SKB500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The administration route of SKB500 is intravenous infusion, with a dosing frequency of Q3W.
Trial: NCT05690334
Drug: Crystalloid - 0 ml/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No fluid coload was given. An initial infusion dose of prophylactic norepinephrine (0.025 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.005 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
Trial: NCT05690334
Drug: Crystalloid - 5 ml/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 ml/kg crystalloid coload combined with an initial infusion dose of prophylactic norepinephrine (0.025 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.005 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
Trial: NCT05690334
Drug: Crystalloid - 10 ml/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml/kg crystalloid coload combined with an initial infusion dose of prophylactic norepinephrine (0.025 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.005 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
Trial: NCT06743867
Drug: Pressurized Intraperitoneal Aerosol Chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The comprehensive therapeutic strategy will be modified based on the integrated 2- or 3-week systemic chemotherapies. In the interim, a total of three PIPAC procedures will be conducted for all qualifying patients.~1. PIPAC combined with 2-week systemic chemotherapies:~   PIPAC therapy will occur every four weeks, while systemic chemotherapies will be administered during the first and third weeks following the initial and second PIPAC procedures respectively.~2. PIPAC combined with 3-week systemic chemotherapies:~(1) Scheme 1: PIPAC therapy will occur every 6 weeks, with systemic chemotherapies administered during the 1st and 4th weeks following the first and second PIPAC procedures, respectively.~(2) Scheme 2: PIPAC therapy will occur every 6 weeks, while systemic chemotherapies will be administered in the 2nd and 5th weeks following the initial and second PIPAC procedures, respectively.
Trial: NCT05097248
Drug: Liposomal Doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposomal Doxorubicin 40 mg/m2 on D1 every 3 weeks; 6 cycles are planned to be completed or discontinued due to intolerable toxicity or progression.
Trial: NCT06731101
Drug: Anticholinergic and Antidepressant Drugs
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tryptizole Librax
Trial: NCT06731556
Drug: Intranasal Diclofenac Sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac sodium at a concentration of 0.0625 mg/mL was administered intranasally.
Trial: NCT06731556
Drug: Intranasal Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen at a concentration of 0.375 mg/mL was administered intranasally.
Trial: NCT06731023
Drug: Other antibiotics
RxNorm normalized name: Other antibiotics for topical use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The selection of other antibiotics is based on the results of drug susceptibility testing.
Trial: NCT06730373
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000 mg/m² Q3W
Trial: NCT06731075
Drug: ORMD-0801 8 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 x 8 mg capsule between 8 PM to 12 Midnight and no sooner than 1 hour after dinner and 2 placebo capsules (1 in the morning and 1 at night).
Trial: NCT06731075
Drug: ORMD-0801 16 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 x 8 mg capsules between 8 PM to 12 Midnight and no sooner than 1 hour after dinner and 1 placebo capsule in the morning.
Trial: NCT06716216
Drug: Drug: 5 mg BGM0504 Administered SC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental: 5 mg BGM0504 5 milligrams (mg) BGM0504 administered subcutaneously (SC) once a week.
Trial: NCT06716216
Drug: Drug:10 mg BGM0504 Administered SC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental: 10 mg BGM0504 10 mg BGM0504 administered SC once a week.
Trial: NCT06705764
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 1.91 ml subcutaneous every 4 weeks. Randomized Control Trial 90 days with Tezepelumab/ Matching Placebo dosing on Day 0, Day 30 and Day 60.
Trial: NCT06705595
Drug: Tracheo-Spray
RxNorm normalized name: bovine type II collagen (tracheal cartilage)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 2 ml of 10% lidocaine delivered via a Tracheo-Spray device to the tracheal mucosa before anesthesia induction.
Trial: NCT06733350
Drug: Therapeutic Testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given via injection, gel, lotion, or transdermal patch
Trial: NCT06733038
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 200 mg/sqm iv over 2 hours day 1
Trial: NCT06733038
Drug: Fluorouracil (5-FU)
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3200 mg/sqm 48 h-continuous infusion, starting on day 1
Trial: NCT06721962
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low dose cyclophosphamide conditioning.
Trial: NCT06209281
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administer to eyes
Trial: NCT06736717
Drug: NALIRIFOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy regimen of nanoliposomal irinotecan, oxaliplatin, fluorouracil \[5-FU\], and leucovorin.~Intravenously on Day 1 of each 14-day cycle.
Trial: NCT06737250
Drug: R2P -> RP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction(R2P) 21 days per cycles, 6 cycles~* NB02 : 60mg BID PO, Day 1-21~* Rituximab 375mg/m2 DAY IV Day 1, 8, 15 at 1st cycle; D1 at 2nd to 6th cycles~* Lenalidomide : 20mg QD PO, Day 1-14~Maintenance(RP) 21 days per cycles, until Progression~* NB02 : 60mg BID PO, Day 1-21~* Lenalidomide : 20mg QD PO, Day 1-14
Trial: NCT04641819
Drug: Yangzheng Compound Mixture
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At the end of the treatment period, the investigator can decide whether to continue the medication based on the improvement of the subjects' sleep disturbance.~Medication during the follow-up period: subjects will enter the follow-up period after completing one course of Yangzheng Compound Mixture treatment or the end of the treatment period. Visits will be conducted once every 3 weeks, at least 2 times and no more than 4 times. For subjects in the experimental group, doctors can decide whether the patients should continue to receive Yangzheng Compound Mixture therapy in the follow-up period according to the improvement of sleep disorders, while for subjects in the control group, the patients can choose to start receiving Yangzheng Compound Mixture therapy in the follow-up period according to their own wishes and doctors' suggestions.
Trial: NCT06739395
Drug: PD-1/PD-L1/PD-1&CTLA4 inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Refer to the respective instructions for use, and the dosage for combined use will be adaptively adjusted by the researcher.Essentially, for de novo combinations, we started patients at about 50% of the usual dose of each drug for two-drug combinations, and at about one-third of the dose of each drug for three-drug combinations. Patients then received escalating doses of drugs to tolerance, while being monitored closely by their treating physicians. Combinations of drugs with overlapping toxicities were avoided.
Trial: NCT06739213
Drug: SYHA1813
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The starting dose of SYHA1813 is 20mg QD
Trial: NCT06739213
Drug: Investigator's Choice Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigator's Choice Treatment
Trial: NCT06735495
Drug: CD19&CD22 bispecific CAR-T cells
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each patient will receive CD19\&CD22 bispecific CAR-T cells by intravenous infusion on day 0
Trial: NCT06735144
Drug: FH-006
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous injection once every two weeks (Q2W), with a treatment period of 28 days
Trial: NCT06735144
Drug: FH-006
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: administered once every 3 weeks (Q3W), with a treatment period of 21 days
Trial: NCT06734572
Drug: 18F-FAPIBiotin
RxNorm normalized name: (18F)-Fluoride
DrugBank: Fluoride ion F-18 (DB09398)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The dose will be 148-296 MBq given intravenously.
Trial: NCT04988308
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered subcutaneously.
Trial: NCT05411965
Drug: BR3003C(R2)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference drug 2 (R2): BR3003C of AstraZeneca Korea
Trial: NCT05329779
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo is a 0.45% sodium chloride infusion.
Trial: NCT06742736
Drug: BGF
RxNorm normalized name: ALCOHOL 620 mg in 1 g TOPICAL AEROSOL, FOAM [GBGF]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BUDESONIDE/GLYCOPYRRONIUM/FORMOTEROL
Trial: NCT05235516
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: q3w iv
Trial: NCT05373199
Drug: Euglycemic clamp with BC Combo THDB0207
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of a single dose of BC Combo THDB0207 during an euglycemic clamp procedure.
Trial: NCT05373199
Drug: Euglycemic clamp with Lantus®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of a single dose of Lantus® during an euglycemic clamp procedure.
Trial: NCT05373199
Drug: Euglycemic clamp with Humalog®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of a single dose of Humalog® during an euglycemic clamp procedure.
Trial: NCT06727396
Drug: Placebo Tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04704063
Drug: Placebo control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching Tocovid Suprabio